We are international
Donate
TEXT SIZE   

Please note: There was a high level of background noise at the venue. Many of these videos have had the audio altered in an attempt to reduce this noise.

ASCO 2006 Front Line Therapy Discussion

Introduction and Overview
An Overview of the Role of Novel Therapies in Untreated Myeloma
Dr. Sundar Jagannath of St. Vincent's Cancer Center in New York discusses the importance of first line novel therapies in attaining complete remission; the importance of complete remission in overall survival; peripheral neuropathy.

IMIDs - Thalidomide (Thalomid®) and Lenalidomide (Revlimid®)
Thal plus dex vs dex alone as initial therapy for newly diagnosed MM
A multicenter, randomized, double-blind, placebo-controlled trial.

Dr. S. Vincent Rajkumar
Mayo Clinic, Rochester, MN
ASCO abstract no. 7517
Symposium Presenter

Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed MM.
Dr. Antonio Palumbo
University of Torino, Torino, ITALY
ASCO Abstract #7518
ASCO Symposium Presenter

Bortezomib (Velcade®)
Single-agent bortezomib in previously untreated MM:
Results of a phase II multicenter study.
Dr. Paul Richardson
Dana Farber Cancer Institute
Boston, MA